title: Amelioration with vessel dilator of acute tubular necrosis and renal failure established for 2 days.
abstract: Seventeen Sprague-Dawley rats had ischemic nonoliguric acute renal failure (ARF) induced by vascular clamping resulting in their preischemic blood urea nitrogen (BUN) and creatinine levels of 16 +/- 1 and 0.56 +/- 0.05 mg/dl to increase to 162 +/- 4 and 8.17 +/- 0.5 mg/dl, P < 0.001, respectively, at day 4 of postischemia. Vessel dilator, a 37-amino-acid cardiac peptide hormone (0.3 microg x kg(-1) x min(-1) ip), decreased the BUN and creatinine levels to 53 +/- 17 mg/dl and 0.98 +/- 0.12 mg/dl (P < 0.001) in another seven animals where ARF had been established for 2 days. Water excretion doubled with ARF and was further augmented by vessel dilator. Transthoracic echocardiography revealed left ventricular dilation as a probable cause of the increase in vessel dilator in the circulation with ARF, and vessel dilator infusion reversed this dilation. At day 6 of ARF, mortality decreased to 14% with vessel dilator from 88% without vessel dilator. Acute tubular necrosis was <5% in the vessel dilator-treated rats compared with 25% to >75% in the placebo-treated ARF animals. We conclude that vessel dilator improves acute tubular necrosis and renal function in established ARF.
authors.affiliation: Departments of Medicine, Pathology, Physiology and Biophysics, University of South Florida Health Sciences Center, Tampa, Florida 33612, USA.
authors.forename: L C
authors.initials: LC
authors.lastname: Clark
authors.forename: H
authors.initials: H
authors.lastname: Farghaly
authors.forename: S R
authors.initials: SR
authors.lastname: Saba
authors.forename: D L
authors.initials: DL
authors.lastname: Vesely
mesh_terms: D058186:Acute Kidney Injury / Q000209:etiology / Q000517:prevention & control*; D000818:Animals; D009320:Atrial Natriuretic Factor / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D004195:Disease Models, Animal; D004452:Echocardiography; D006321:Heart / Q000187:drug effects / Q000503:physiopathology; D006439:Hemodynamics / Q000187:drug effects; D007511:Ischemia / Q000188:drug therapy / Q000473:pathology; D007668:Kidney / Q000098:blood supply / Q000187:drug effects / Q000473:pathology; D007677:Kidney Function Tests; D007683:Kidney Tubular Necrosis, Acute / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D008297:Male; D010446:Peptide Fragments / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D011498:Protein Precursors / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D051381:Rats; D017207:Rats, Sprague-Dawley; D014665:Vasodilator Agents / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*
chemical_list: D010446:Peptide Fragments; D011498:Protein Precursors; D014665:Vasodilator Agents; C054548:atrial natriuretic factor prohormone (31-67); D009320:Atrial Natriuretic Factor